Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome

References

• Taylor A E. Polycystic ovary syndrome. Endocrinol Metab North Am 1998; 27: 877–902
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Zawadsky J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome, A Dunaif, J R Givens, F P Haseltine, G R Merriam. Blackwell Scientific Publications, CambridgeUK 1992; 377–384
   Google Scholar
• Baillargeon J P, Iuorno M J, Nestler J E. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325–340
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114–119
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni V M. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007; 23: 146–152
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–1174
   PubMed Web of Science ®Google Scholar
• De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. End Rev 2003; 24: 633–667
   PubMed Web of Science ®Google Scholar
• Ciampelli M, Fulghesu A M, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A, Lanzone A. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999; 48: 167–172
   PubMed Web of Science ®Google Scholar
• Romero G, Larner J. Insulin mediators and the mechanism of insulin action. Adv Pharmacol 1993; 24: 21–50
   PubMedGoogle Scholar
• Saltiel A R. Second messengers of insulin action. Diabetes Care 1990; 13: 244–256
   PubMed Web of Science ®Google Scholar
• Kennington A S, Hill C R, Craig J, Bogardus C, Raz I, Ortmeyer H K, Hansen B C, Romero G, Larner J. Low urinary chiroinositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 373–378
   PubMed Web of Science ®Google Scholar
• Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993; 90: 5924–5928
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314–1320
   PubMed Web of Science ®Google Scholar
• Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8: 417–423
   PubMedGoogle Scholar
• Baillargeon J P, Diamanti-Kandarakis E, Ostlund R E, Apridonidze T, Iuorno M J, Nestler J E. Altered D-Chiro-Inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29: 300–305
   PubMed Web of Science ®Google Scholar
• Gerli S, Mignosa M, Di Renzo G C. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003; 7: 151–159
   PubMedGoogle Scholar
• Chiu T TY, Rogers M S, Law E LK, Briton-Jones C M, Cheung L P, Haines C J. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002; 6: 1591–1596
   Google Scholar
• Chiu T TY, Rogers M S, Briton-Jones C, Haines C. Effects of myo-inositol in the in-vitro maturation and subsequent development of mouse oocyte. Hum Reprod 2003; 18: 408–416
   PubMed Web of Science ®Google Scholar
• Haffner S M, Miettinem H, Stern M P. The homeostasis model in the San Antonio Hearth Study. Diabetes Care 1997; 20: 1087–1092
   PubMed Web of Science ®Google Scholar
• Legro R S, Finegood D, Dunaif A. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694–2698
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Fabbri G, Monzani A, Montanini V, Genazzani A R. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril 1990; 54: 222–226
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Benatti R, Montanini V, Algeri I, Volpe A, Genazzani A R. Luteinizing hormone (LH) secretory burst duration is indipendent from LH, prolactin or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab 1991; 72: 1220–1225
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Pianazzi F, Volpogni C, Genazzani A R. The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatilee releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol 1993; 7: 33–41
   PubMed Web of Science ®Google Scholar
• Baker L, Piddington R, Goldman A, Egler J, Moehring J. Myo-Inositol and prostaglandin reverse the glucose inhibition of neural tube fusion in cultured mouse embryos. Diabetologia 1990; 33: 593–596
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba A J, Spaczynski R Z, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149–1154
   PubMed Web of Science ®Google Scholar
• Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar Morreale H-F, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–2438
   PubMed Web of Science ®Google Scholar
• Knochenhauser E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the south-eastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Nestler J E. Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes 2000; 7: 345–349
   Google Scholar
• Dunaif A, Xia J, Book C B, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblast and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801–810
   PubMed Web of Science ®Google Scholar
• Lobo R A, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989–993
   PubMed Web of Science ®Google Scholar
• Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistancerelated polycystic ovary syndrome. Fertil Steril 1999; 71: 323–327
   PubMed Web of Science ®Google Scholar
• Mitwally M F, Kuscu N K, Yalcinkaya T M. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999; 14: 2700–2703
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Schneider D J, Sobel B E, Cavaghan M K, Imperial J, Rosenfield R L, Polonski K S. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108–2116
   PubMed Web of Science ®Google Scholar
• Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299–3306
   PubMed Web of Science ®Google Scholar
• Nestler J E, Powers L P, Matt D W, Steingold K A, Plymates R, Rittmaster R S, Clore J N, Blackand W G. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83–89
   PubMed Web of Science ®Google Scholar
• Larner J. Insulin-signaling mechanisms: lessons from the old testament of glycogen metabolism and the new testament of molecular biology. Diabetes 1988; 37: 262–275
   PubMed Web of Science ®Google Scholar
• Saltiel A R. Second messengers of insulin action. Diabetes Care 1990; 13: 244–256
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Beillargeon J P, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome a novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700–703
   Google Scholar